Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Chemotherapie  (2)
  • Combination chemotherapy  (2)
  • Drug resistance  (2)
  • Phase II study  (2)
  • 1
    Electronic Resource
    Electronic Resource
    Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines (2000)
    Springer
    Journal of cancer research and clinical oncology 126 (2000), S. 198-204 
    Details
    ISSN: 1432-1335
    Keywords: Key words DNA repair ; Resistance modifier ; Drug resistance
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose: Modulation of DNA repair represents one strategy to overcome cellular drug resistance to alkylating agents and platinum compounds. The effects of different known DNA repair modulators such as O 6-benzylguanine (6 μg/ml), fludarabine (25 ng/ml), aphidicolin (8.5 ng/ml), pentoxifylline (1.4 μg/ml) and methoxamine (12.4 μg/ml) on the cytotoxicity of mafosfamide, chlorambucil, 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), cisplatin and carboplatin were tested in human lung cancer cell lines. Methods: Chemosensitivity of the human adenocarcinoma cell line MOR/P and the cisplatin-resistant subline MOR/CPR as well as the large-cell lung cancer cell line L23/P and its cisplatin-resistant counterpart L23/CPR were evaluated by the MTT colorimetric assay. Results: O 6-benzylguanine, an inhibitor of O 6-alkylguanine-DNA alkyltransferase, significantly sensitised MOR/P and MOR/CPR cells to the cytotoxic effect of BCNU. Fludarabine, methoxamine and aphidicolin did not change the chemosensitivity of the parental and cisplatin-resistant cell lines to any cytotoxic drug tested. Interestingly, O 6-benzylguanine enhanced the chemoresistance of parental and cisplatin-resistant cell lines to platinum compounds. Also, pentoxifylline increased resistance of the MOR cell lines to mafosfamide. Conclusions: Modulation of DNA repair elicits not only chemosensitisation but may also enhance cellular resistance to DNA-affine drugs.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s004320050033
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: Chemosensitization by verapamil in relation to P-glycoprotein expression (1992)
    Springer
    Annals of hematology 65 (1992), S. 206-212 
    Details
    ISSN: 1432-0584
    Keywords: P-glycoprotein ; Drug resistance ; MTT assay ; Acute myeloid leukemia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A 4-day colorimetric tetrazolium dye (MTT) assay was used to assess the cytotoxicity of adriamycin (ADM), vincristine (VCR), and idarubicin (IDA) in blasts isolated from 37 patients with newly diagnosed and pretreated acute myeloid leukemia (AML). The effect of verapamil (VRP) as a chemosensitizer was studied in relation to the expression of the membrane efflux pump P-glycoprotein (PGP) as determined by a semiquantitative flow-cytometric procedure. A slight positive correlation was found between the fraction of cells expressing PGP and the ID50 values for ADM and VCR, but not between cellular PGP content and sensitivity to IDA. The overall data showed no significant sensitization effect of VRP. However, in specimens with more than 10% cells expressing PGP, 2μM VRP sensitized cells to ADM and VCR significantly. The median of sensitization ratios (SRs), i.e., the ratios of cytotoxic drug ID50 in the absence/presence of VRP, were 1.89 and 2.0, respectively. No sensitizing effect of VRP on the cytotoxicity of IDA was observed. Related to the clinical status, the median fraction of PGP-positive blasts was elevated fourfold in pretreated patients (n=16) in comparison to patients with de novo AML (n=19). No differences in ID50 values were observed between newly diagnosed and pretreated patients. However, SRs for ADM and VCR were higher in samples of pretreated patients compared with de novo AML. PGP-mediated cellular drug resistance may thus be circumvented in leukemic blasts by application of chemosensitizers or, potentially, alternative anthracyclines.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01703946
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Phase II trial of aclacinomycin A in acute leukemia and various solid tumors (1983)
    Springer
    Journal of cancer research and clinical oncology 105 (1983), S. 162-165 
    Details
    ISSN: 1432-1335
    Keywords: Aclacinomycin A ; Phase II study ; Refractory neoplasms
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Aclacinomycin A (ACM) is a new anthracycline antibiotic with a reduced cardiac toxicity in animal models. A phase II study was performed in a total of 25 patients, 23 of whom are evaluable for response. All suffered from recurrent and advanced tumors. Pretreatment consisted of at least four different chemotherapeutic agents (range: 4–9). Lung cancer patients (3/9) were irradiated to the mediastinum. Eighteen patients were pretreated with doxo- or daunomycin. The dose for solid tumors was 2–3 mg/kg given on 3 consecutive days every 3 weeks. Leukemia patients received a daily dose of 20 mg/m2, and standard response criteria were used. Marked reductions of leukocyte counts were achieved in leukemia patients. The overall response rate was about 15% in solid tumors, but major objective responses (CR+PR) have not been observed. Myelosuppression was commonly moderate in solid tumor patients, nausea and vomiting were rare, and alopecia was not induced. Cumulative cardiotoxicity was not evaluated in this trial. Treatment with ACM requires further investigation in acute leukemias and solid tumors, not pretreated with anthracycline antibiotics.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00406927
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Sequentiell alternierende Chemotherapie nicht-seminomatöser Hodentumoren mit Velbe/Bleomycin und Adriamycin/Cisplatin (1980)
    Springer
    Journal of molecular medicine 58 (1980), S. 823-828 
    Details
    ISSN: 1432-1440
    Keywords: Testicular neoplasms ; Stage II ; Combination chemotherapy ; Radiotherapy ; Lymph node dissection ; Testikuläre Tumoren ; Stadium II ; Kombinierte Chemotherapie ; Radiotherapie ; Lymphknoten-Exstirpation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Seit 1975 wurden 140 Patienten mit retroperitoneal-metastasierten nicht-seminomatösen Hodentumoren nach Orchiektomie und retroperitonealer Lymphadenektomie sequentiell alternierend mit den Zytostatika-Kombinationen Velbe/Bleomycin und Adriamycin/Cisplatin plus/minus Radiotherapie behandelt. Davon erhielten 68 Patienten nach totaler retroperitonealer Lymphadenektomie mit postoperativ normalisierten Tumormarkern (Stadium IIA) 6 Chemotherapie-Kurse, woran sich bei 35 Patienten eine Strahlentherapie anschloß. Vierzig Patienten wurden nach subtotaler retroperitonealer Lymphadenektomie oder bei postoperativ erhöhten Tumormarkern (Stadium IIB) und 32 Patienten nach palliativer Lymphadenektomie (Stadium IIC) mit mindestens 12 Chemotherapie-Kursen und fakultativer intermittierender Radiotherapie und/oder Relaparotomie behandelt. Der Vergleich der Behandlungsergebnisse bei den Stadien IIA und IIB ergab unabhängig von der zusätzlichen Radiotherapie nach der „Life-table“-Methode Vier-Jahres-Überlebensraten zwischen 80 und 100%. Diese günstigen Resultate sind mit den Ergebnissen bei 34 nicht adjuvant behandelten Patienten ohne histologisch nachweisbare retroperitoneale Metastasierung (Stadium I) vergleichbar. Ausdruck einer statistisch signifikant schlechteren Prognose bei fortgeschrittener retroperitonealer Metastasierung ist eine Vier-Jahres-Überlebensrate von 12% bei den Patienten im Stadium IIC.
    Notes: Summary Following orchiectomy and retroperitoneal lymph node dissection (RND) 140 patients with stage II non-seminomatous testicular cancer were treated by sequential combination chemotherapy consisting of vinblastine/bleomycin and adriamycin/cis-dichlorodiammineplatinum(II) (DDP), plus/minus radiotherapy. 68 stage IIA-patients (complete RND and normal tumor-markers thereafter) received 6 courses of chemotherapy, followed by radiotherapy in 35 patients. 40 stage IIB-patients (minor residual disease after RND or elevated tumor-markers after RND) and 32 stage IIC-patients (advanced residual disease after RND) were treated by at least 12 chemotherapy courses and optional intermittent radiotherapy and/or relaparotomy. In stage IIA and IIB disease the actuarial 4-year survival rates were between 80 and 100%. These favourable results were not significantly influenced by additional radiotherapy and corresponded to the survival rates for 34 stage I-patients. For stage IIC-patients the prognosis was significantly worse with a 12% 4-year survival rate.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01491102
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Sequentiell alternierende Chemotherapie nicht-seminomatöser Hodentumoren mit Velbe/Bleomycin und Adriamycin/Cisplatin (1980)
    Springer
    Journal of molecular medicine 58 (1980), S. 811-821 
    Details
    ISSN: 1432-1440
    Keywords: Testicular neoplasms ; Stage IV ; Combination chemotherapy ; Prognosis ; Cross-resistance ; Testikuläre Tumoren ; Stadium IV ; kombinierte Chemotherapie ; Prognose ; Kreuzresistenz
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Vierundsiebzig Patienten mit pulmonal metastasierten nicht-seminomatösen Hodentumoren wurden im Rahmen einer prospektiven randomisierten Phase III-Studie sequentiell alternierend mit Velbe/Bleomycin und Adriamycin/Cisplatin behandelt. Unabhängig von der Randomisierung der initialen Zytostatika-Kombination wurden bei 71 auswertbaren Patienten bei einer Ansprechrate von 89% in 54% der Fälle Vollremissionen erzielt, die bei 35% der Patienten zwischen 2+ und 28+ Monaten mit einem Median von 12 Monaten andauerten. Durch zusätzliche operative Entfernung residueller pulmonaler Solitärmetastasen wurde die Vollremissionsrate auf 40/71 (56%) und die Anzahl der andauernden Vollremissionen auf 27/71 (38%) erhöht. Die Zwei-Jahres-Überlebensrate betrug nach der „Life-table“-Methode 63% bei den Patienten, bei denen eine Vollremission erreicht wurde, und war mit 29% bei den übrigen Patienten statistisch signifikant niedriger. Dreiundfünfzig Patienten (75%) waren bei einer mittleren Überlebenszeit von 9 Monaten zwischen 3 und 28 Monaten am Leben. Zusätzliche fortgeschrittene abdominelle Metastasierung, initial erhöhte β-HCG-und LDH-Werte und das Ausmaß der pulmonalen Metastasierung beeinflußten die Prognose statistisch signifikant negativ. Die Auswertung der einzelnen Chemotherapie-Kurse zeigte, daß beide Zytostatika-Kombinationen gleich wirksam waren. Dabei war jedoch ein Ansprechen auf Adriamycin/Cisplatin in 46% der Fälle nachweisbar, in denen Velbe/Bleomycin versagt hatte, während Velbe/Bleomycin nur bei 21% der Fälle wirksam war, in denen Adriamycin/Cisplatin zu keinem Ansprechen geführt hatte. Eine unterschiedlich ausgeprägte Kreuzresistenz zwischen den beiden Zytostatika-Kombinationen muß daher angenommen werden.
    Notes: Summary 74 patients with disseminated non-seminomatous testicular cancer were randomly entered on a prospective sequential combination chemotherapy regimen with mandatory crossover, consisting of either vinblastine/bleomycin or adriamycin/cis-dichlorodiammineplatinum (II) (DDP) as initial therapy. Independent of the randomization the overall remission rate in 71 evaluable patients was 89% including 54% complete remissions. 35% of the patients remained disease-free at 2+ to 28+ months with a median of 12 months. By additional surgical removal of residual pulmonary metastases in two patients the complete remission rate was increased to 40/71 (56%), and the number of patients with no evidence of disease to 27/71 (38%). According to the life-table method the two-years survival rates were 63% for complete responders and 29% for all other patients, which was significantly lower. 53 patients (75%) were alive at 3 to 28 months with a median of 9 months. Additional advanced abdominal disease, initially elevated β-HCG and LDH and extension of pulmonary disease were of significant negative influence on the prognosis. The evaluation of single chemotherapy courses revealed equal efficacy of both combinations. However, response to adriamycin/DDP occurred in 46% of the courses, when vinblastine/bleomycin had failed, while response to vinblastine/bleomycin occurred only in 21% of the courses when adriamycin/DDP had failed. Thus different patterns of cross-resistance between these alternative regimens may exist.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01491101
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Phase II evaluation of fractionated low and single high dose cisplatin in various tumors (1984)
    Springer
    Journal of cancer research and clinical oncology 107 (1984), S. 57-60 
    Details
    ISSN: 1432-1335
    Keywords: Cisplatin ; Phase II study ; Solid tumors
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Seventy-three evaluable patients with advanced measurable solid tumors were given cisdichlorodiammineplatinum (II) (DDP) at a dose of 20 mg/M2 IV for 1–5 days every 3 weeks, and 19 patients who failed on this low dose DDP protocol received a single high dose of 100 mg/M2 IV once every 3 weeks. Forty-six patients had received prior chemotherapy, and 29 patients were untreated. Results included four complete responses (5.5%) in malignant melanoma, spindle-cell sarcoma, adrenal carcinoma, and bladder carcinoma lasting 2 to 4 months. In 21 patients (28.8%), partial responses were achieved. Twenty-two patients (30.1%) showed stable disease and 26 (35.6%) had tumor progression. A response rate of 25% (4/16 patients) was found for malignant melanoma, 45.5% (5/11) for nonsmall-cell lung cancer, and 35.3% (6/17) for sarcomas of various types. One patient with teratocarcinoma, who relapsed on low-dose DDP, had another partial remission for 4 months after high-dose therapy. Toxicity was most commonly seen with gastrointestinal side effects and myelosuppression. Cumulative nephrotoxicity was prevented by prehydration and/or treatment with furosemide or mannitol.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00395492
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Pronounced antiemetic activity of the antipsychotic drug levomepromacine (L) in patients receiving cancer chemotherapy (1980)
    Springer
    Journal of cancer research and clinical oncology 97 (1980), S. 81-86 
    Details
    ISSN: 1432-1335
    Keywords: Chemotherapie ; Antiemese ; Levomepromazin ; Chemotherapy ; Antiemetics ; Levomepromacine
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary The antiemetic quality of the orally administered phenothiazine derivative levomepromacine was studied under clinical conditions in cancer patients receiving either cisplatin alone, ifosfamide alone or adriamycincontaining combinations. Seventy of 113 evaluable patients (62%)-all refractory to conventional antiemetics-were fully protected from nausea and vomiting when levomepromacine (2×8–15 mg) was administered in two steps (12 h and 1 h before the cytotoxic agents). Another 34% of all patients showed considerable improvement with respect to gastrointestinal side effects. The most pronounced effect with levomepromacine was seen in patients treated with a 20 mg/m2 daily×5 schedule of cisplatin but complete or partial relief was also seen with high single cisplatin doses of 50–100 mg/m2. In addition, the antiemetic showed effectiveness against nausea and vomiting induced by other agents, such as adriamycin or isofosfamide. Although a final evaluation of the antiemetic effect of levomepromacine will have to be based on a double-blind study, these initial observations have already been of great value for many patients.
    Notes: Zusammenfassung Unter stationär-klinischen Bedingungen wurde die zufällig beobactete antiemetische Qualität des oral angewandten Phenothiazinderivats Levomepromazin bei Tumorpatienten untersucht, welche entweder mit Cisplatin, Iphosphamid oder Adriamycin-haltigen Kombinationen behandelt wurden. Alle auswertbaren Patienten waren refraktät genenüber konventionellen Antiemetika. Bei einer Gesamtzahl von 113 Patienten konnte in insgesamt 70 Fällen (62%) ein voller Schutz vor Übelkeit und Erbrechen durch eine zweimalige Anwendung von Levomepromazin in einer Dosierung von 8–15 mg je 12 Std und 1 Std vor Beginn der Chemotherapie bewirkt werden. Bei weiteren 34% aller Patienten war eine deutliche subjektive Besserung hinsichtlich der gastrointestinalen Nebenwirkungen zu verzeichnen. Am ausgeprägtesten war der antiemetische Effekt von Levomepromazin bei Patienten unter konventioneller Cisplatin-Therapie (20 mg/m2 täglich×5), jedoch konnte eine eindeutige Wirkung auch bei hohen Cisplatindosen bis 100 mg/m2, welche normalerweise zusehr starken Nebenerscheinungen führten, nachgewiesen werden. Darüber hinaus war der antiemetische Effekt von Levomepromazin auch gegen Übelkeit und Erbrechen im Zusammenhang mit Adriamycin oder Iphosphamid wirkungsvoll. Obwohl eine endgültige Beurteilung des antiemetischen Effekts von Levomepromazin erst auf der Basis einer Doppelblindstudie möglich sein wird, was das Medikament bereits bei zahlreichen Patienten von großem Wert für die praktische Durchführung einer effektiven Zytostatikathepie.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00411281
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma (1980)
    Springer
    Journal of cancer research and clinical oncology 97 (1980), S. 301-306 
    Details
    ISSN: 1432-1335
    Keywords: Malignes Melanom ; Chemotherapie ; Ifosfamid ; Cisplatin ; Malignant melanoma ; Chemotherapy ; Ifosfamide ; Cisplatin
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Twenty-five patients with measurable lesions of advanced malignant melanoma received a combined chemotherapy containing cis-dichlordiammineplatinum (II) (cisplatin) 30 mg daily at days 1, 3, 5, 7, 9, and ifosfamide 45 mg/kg at days 2, 4, 6, 8, and 10. Most of the patients had been previously treated with DTIC or DTIC-containing combinations. An objective response was observed in 10 patients including three complete and seven partial remissions. Medium survival was 3 months for nonresponders and 6 months for responders. Nausea and vomiting during chemotherapy could be reduced effecttively by the use of levomepromacine (Neurocil). Hematologic toxicity was considerable in extensively pretreated patients and made it necessary to postpone subsequent courses in two cases.
    Notes: Zusammenfassung Fünfundzwanzig Patienten mit metastasierendem malignem Melanom und gut dokumentierbaren Tumorparametern wurden mit einer kombinierten zytostatischen Chemotherapie, bestehend aus Cisplatin und Ifosfamid, behandelt. Cisplatin wurde an den Tagen 1, 3, 5, 7 und 9 in der Tagesdosis von 30 mg und Ifosfamid in einer Dosis von 45 mg/kg an den Tagen 2, 4, 6, 8 und 10 verabreicht. Die meisten Patienten waren zuvor mit DTIC oder DTIC-haltigen zytostatischen Kombinationen behandelt worden. In drei Fällen wurde eine komplette Remission und in sieben Fällen eine Teilremission mit über 50% Tumorreduktion erreicht. Die mittlere Überlebenszeit betrug für therapieresistente Fälle 3 Monate und für Ansprecher 6 Monate. Erbrechen und Übelkeit während der Behandlung konnte durch die Verabreichung von Levomepromazin (Neurocil) reduziert werden. Die hämatologische Toxizität war bei intensiv vorbehandelten Patienten erheblich und machte eine Verlängerung des therapiefreien Intervalls in zwei Fällen erforderlich.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00405782
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...